Protalex Inc.

PRTX on OTCQBToday's ChangeVolume52 Week Range (Low/Hi)Market Cap
0.75US 0.00/0.00%00.31 / 3.0021.58 M
Powered by: Google Finance

Contact Information

Protalex Inc.

Headquarters:
131 Columbia Turnpike, Suite 1
Florham Park, New Jersey
USA, 07932
Tel: 215-862-9720
Email: Send a message
Website: Visit website
For more information...
Lead: Robert Thaemlitz

Protalex, Inc. is a clinical-stage biopharmaceutical company focused on the development of a class of drugs for treating autoimmune and inflammatory diseases including Rheumatoid Arthritis (RA) and Immune Thrombocytopenia (ITP). Protalex’s lead product candidate, PRTX-100, is a highly purified form of Staphylococcal Protein A, which is an immunomodulatory protein produced by bacteria known to modify aspects of the human immune system. PRTX-100 has the ability, at very low concentrations, to bind to human B-lymphocytes and macrophages and to modulate immune processes. In two Phase 1b clinical trials in adult patients with active RA, PRTX-100 was found generally safe and well tolerated at all dose levels, and at certain higher doses, more patients showed improvement in measures of RA disease activity than did patients at the lower dose or placebo cohorts. The safety, tolerability and pharmacokinetics of PRTX-100 have now been characterized in six clinical studies and was granted Orphan Drug Designation (ODD) in the United States and Europe for the treatment of ITP. 

Arnold P. Kling - President and Director

Kirk M. Warshaw - Chief Financial Officer, Secretary and Director

William E. Gannon, JR., M.D. - Chief Medical Officer

Richard Francovitch, Ph.D - Vice President of ITP Programs

Arnold P. Kling - President and Director

Kirk M. Warshaw - Chief Financial Officer, Secretary and Director

Macro M. Elser - Director

 

Scientific Advisory Board

James W. Dowe III - Vice Chairman of Scientific Advisory Board

Benjamin R. Bowen, Ph.D - Chairman of Scientific Advisory Board

Stock Information

PRTX on OTCQB
0.75US
Today's Change
0.00/0.00%
Volume
0
52 Week Range (Low/Hi)
0.31 / 3.00
Market Cap
21.58 M

Company Overview

Protalex, Inc. is a clinical-stage biopharmaceutical company focused on the development of a class of drugs for treating autoimmune and inflammatory diseases including Rheumatoid Arthritis (RA) and Immune Thrombocytopenia (ITP). Protalex’s lead product candidate, PRTX-100, is a highly purified form of Staphylococcal Protein A, which is an immunomodulatory protein produced by bacteria known to modify aspects of the human immune system. PRTX-100 has the ability, at very low concentrations, to bind to human B-lymphocytes and macrophages and to modulate immune processes. In two Phase 1b clinical trials in adult patients with active RA, PRTX-100 was found generally safe and well tolerated at all dose levels, and at certain higher doses, more patients showed improvement in measures of RA disease activity than did patients at the lower dose or placebo cohorts. The safety, tolerability and pharmacokinetics of PRTX-100 have now been characterized in six clinical studies and was granted Orphan Drug Designation (ODD) in the United States and Europe for the treatment of ITP. 

Management

Arnold P. Kling - President and Director

Kirk M. Warshaw - Chief Financial Officer, Secretary and Director

William E. Gannon, JR., M.D. - Chief Medical Officer

Richard Francovitch, Ph.D - Vice President of ITP Programs

Board of Directors

Arnold P. Kling - President and Director

Kirk M. Warshaw - Chief Financial Officer, Secretary and Director

Macro M. Elser - Director

 

Scientific Advisory Board

James W. Dowe III - Vice Chairman of Scientific Advisory Board

Benjamin R. Bowen, Ph.D - Chairman of Scientific Advisory Board

Contact Information

Headquarters:
131 Columbia Turnpike, Suite 1
Florham Park, New Jersey
07932, USA
Telephone: 215-862-9720
Email: Send a message
Website: Visit website